Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Huafeng Wang, Xudong Wei, Yang Liang, Jianyu Weng, Wenjuan He, Chunkang Chang, Suning Chen, Hongbing Ma, Zi Chen, Lichuang Men, Lihui Liu, Xiaohong Tian, Zhang Zhang, Danhua Cong, Dajun Yang, Yifan Zhai, Jie Jin

Blood (2024) 144 (Supplement 1): 3202.

https://doi.org/10.1182/blood-2024-205371

Published: 2024

Journal Articles

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Blood (2024) 144 (Supplement 1): 304.

https://doi.org/10.1182/blood-2024-206377

Published: 2024

Journal Articles

Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study

Chunkang Chang, Min Zhang, Sujun Gao, Luxi Song, Duoer Wu, Dawei Ding, Shanli Lao, Ding Yu

Blood (2024) 144 (Supplement 1): 484.

https://doi.org/10.1182/blood-2024-203242

Published: 2024

Journal Articles

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

Wenbing Duan, Chunkang Chang, Zhiguo Wang, Hongbing Ma, Min Ouyang, Xingli Zhao, Lifan Tu, Guodong Wu, Xunqiang Wang, Xiao Jun Huang, Hao Jiang

Blood (2024) 144 (Supplement 1): 1504.

https://doi.org/10.1182/blood-2024-204972

Published: 2024

Journal Articles

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Mingyuan Sun, Lugui Qiu, Keshu Zhou, Kai Hu, Chunkang Chang, Dong Wu, Zhenling Li, Ming Gong, Wenjun Zhang, Daniel Yang, Jiali Lu, Junyuan Qi

Blood (2024) 144 (Supplement 1): 3103.

https://doi.org/10.1182/blood-2024-193606

Published: 2024

Journal Articles

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

Blood (2024) 144 (Supplement 1): 4748.

https://doi.org/10.1182/blood-2024-202893

Published: 2024

Journal Articles

The Mechanism of Setd2 in Mesenchymal Stromal Cell in MDS-Associated Ineffective Hematopoiety

Roujia Wang, Lan Wang, Chunkang Chang

Blood (2023) 142 (Supplement 1): 6460.

https://doi.org/10.1182/blood-2023-184439

Published: 2023

Journal Articles

MDS-MSC Derived Exosomes Promote MDS Cells Malignant Proliferation through RIG-1/Isgs Pathway Via RN7SL1

Juan Guo, Jianxiang Wang, Chunkang Chang

Blood (2023) 142 (Supplement 1): 6461.

https://doi.org/10.1182/blood-2023-185531

Published: 2023

Journal Articles

First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study

Zefeng Xu, Ling Pan, Zhenya Hong, Qingsong Yin, Xuelan Zuo, Qin Wen, Fan Yu, Chunkang Chang, Wei Ling, Dong Wang, Dawei Ding, Zhijian Xiao

Blood (2023) 142 (Supplement 1): 1829.

https://doi.org/10.1182/blood-2023-178956

Published: 2023

Journal Articles

EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma

Junyuan Qi, Mingyuan Sun, Keshu Zhou, Chunyan Ji, Fei Lu, Chunkang Chang, Wenjun Zhang, Daniel Yang, Jiali Lu, Jisen Li, Ying Cheng, Yanfei Li

Blood (2023) 142 (Supplement 1): 6230.

https://doi.org/10.1182/blood-2023-173486

Published: 2023

Journal Articles

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Blood (2023) 142 (Supplement 1): 320.

https://doi.org/10.1182/blood-2023-174420

Published: 2023

Journal Articles

Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)

Blood (2022) 140 (Supplement 1): 8821–8822.

https://doi.org/10.1182/blood-2022-163880

Published: 2022

Journal Articles

Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Hao Jiang, Xudong Wei, Chunkang Chang, Hongbing Ma, Xuejun Zhang, Xiao-Jun Huang

Blood (2022) 140 (Supplement 1): 9082–9083.

https://doi.org/10.1182/blood-2022-164984

Published: 2022

Journal Articles

Combination Therapy of Eltrombopag and Cyclosporine a Improves Hematopoiesis in Patients with Lower-Risk Myelodysplastic Syndrome

Luxi Song, Chunkang Chang, Jianxiang Wang

Blood (2022) 140 (Supplement 1): 4084–4085.

https://doi.org/10.1182/blood-2022-168147

Published: 2022

Journal Articles

Incorporation of Mutations and Bone Marrow Fibrosis into the Revised International Prognostic Scoring System in Patients with Myelodysplastic Syndromes

Youshan Zhao, ChunKang Chang

Blood (2022) 140 (Supplement 1): 4063–4064.

https://doi.org/10.1182/blood-2022-165202

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 4045–4046.

https://doi.org/10.1182/blood-2022-155901

Published: 2022

Journal Articles

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Blood (2021) 138 (Supplement 1): 2480.

https://doi.org/10.1182/blood-2021-149861

Published: 2021

Journal Articles

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

Blood (2021) 138 (Supplement 1): 4770.

https://doi.org/10.1182/blood-2021-145282

Published: 2021

Journal Articles

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

Blood (2021) 138 (Supplement 1): 4778.

https://doi.org/10.1182/blood-2021-146784

Published: 2021

Journal Articles

DNMT3A wt NPM1-Mutation Defines a Subgroup of MDS with Special Favorable Outcomes Towards Decitabine Therapy

Lingyun Wu, MD PhD, Xiao Li, MD, Feng Xu, He Qi, Zheng Zhang, Dong Wu, Luxi Song, MD, Liyu Zhou, Chao Xiao, Jiying Su, Juan Guo, Chunkang Chang

Blood (2019) 134 (Supplement_1): 1724.

https://doi.org/10.1182/blood-2019-124008

Published: 2019

NARROW

Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor, in Combination with Azacitidine in Treatment of Patients with Myelodysplastic Syndrome (MDS)

Hetrombopag Added to Immunosuppressive Therapy in First-Line Treatment of Severe Aplastic Anemia: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial

Rovadicitinib in Patients with Myelofibrosis Who Were Refractory or Relapsed or Intolerant to Ruxolitinib: A Single Arm, Multicenter, Open-Label, Phase Ib Study

TQB3455 Plus Azacitidine in Patients with Newly Diagnosed, Mutant-IDH2 Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Phase 1 Trial

EX103, a Newly Re-Designed CD20×CD3 Molecule, Induces High Response in Heavily Pretreated Relapsed/Refractory (R/R) Patients with B-Cell Non-Hodgkin Lymphoma (B-NHL)

Weekly Selinexor, Bortizomib and Dexamethasone (SVd) Versus Twice Weekly Bortizomib and Dexamethasone (Vd) in Chinese Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Primary Analysis of Phase 3 Bench Study

The Mechanism of Setd2 in Mesenchymal Stromal Cell in MDS-Associated Ineffective Hematopoiety

MDS-MSC Derived Exosomes Promote MDS Cells Malignant Proliferation through RIG-1/Isgs Pathway Via RN7SL1

First-in-Class JAK/Rock Inhibitor Rovadicitinib in Myeloproliferative Neoplasms: A Single Arm, Multicenter, Open-Label, Phase I/Ib Study

EX103, a Novel CD20xCD3 Bispecific Antibody, Showed a Favorable Safety and Potent Single-Agent Antitumor Activity in Heavily Pretreated Relapsed/Refractory Patients with B-Cell Non-Hodgkin Lymphoma

Preliminary Results of a Phase 2 Study of IMM01 Combined with Azacitidine (AZA) As the First-Line Treatment in Adult Patients with Higher Risk Myelodysplastic Syndromes (MDS)

Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)

Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Combination Therapy of Eltrombopag and Cyclosporine a Improves Hematopoiesis in Patients with Lower-Risk Myelodysplastic Syndrome

Incorporation of Mutations and Bone Marrow Fibrosis into the Revised International Prognostic Scoring System in Patients with Myelodysplastic Syndromes

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Efficacy and Safety of Recombinant Human-Mouse Chimeric Anti-CD20 Monoclonal Antibody (SCT400) Combined with CHOP in Patients with Treatment-Naïve Diffuse Large B-Cell Lymphoma: A Multicenter, Randomized, Single-Blind, Parallel Active-Controlled, Phase III Study

Phase 2 March Study: ATG-010 Plus Low Dose Dexamethasone in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Treated with an Immunomodulatory Agent (IMiD) and a Proteasome Inhibitor (PI)

ATG-010 Plus Low-Dose Dexamethasone (Sd) in Chinese Relapsed/Refractory Multiple Myeloma (RRMM) Patients Previously Received Chimeric Antigen Receptor T-Cell (CAR-T)

DNMT3A wt NPM1-Mutation Defines a Subgroup of MDS with Special Favorable Outcomes Towards Decitabine Therapy

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only